Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

Mitophagy inhibits amyloid-β and tau pathology and reverses cognitive deficits in models of Alzheimer's disease.

Fang EF, Hou Y, Palikaras K, Adriaanse BA, Kerr JS, Yang B, Lautrup S, Hasan-Olive MM, Caponio D, Dan X, Rocktäschel P, Croteau DL, Akbari M, Greig NH, Fladby T, Nilsen H, Cader MZ, Mattson MP, Tavernarakis N, Bohr VA.

Nat Neurosci. 2019 Mar;22(3):401-412. doi: 10.1038/s41593-018-0332-9. Epub 2019 Feb 11.

PMID:
30742114
2.

Oral Medicine for undergraduate dental students in the United Kingdom and Ireland-A curriculum.

Mighell AJ, Freeman C, Atkin PA, Bennett JH, Buchanan JAG, Carrozzo M, Crighton AJ, Escudier MP, Gibson J, Healy CM, Hegarty AM, Kerr JS, McCreary CE, Pemberton MN, Rajlawat B, Richards A, Staines K, Theaker ED, Willis A.

Eur J Dent Educ. 2018 Nov;22(4):e661-e668. doi: 10.1111/eje.12366. Epub 2018 Jun 6.

PMID:
29877053
3.

In Vitro and In Vivo Detection of Mitophagy in Human Cells, C. Elegans, and Mice.

Fang EF, Palikaras K, Sun N, Fivenson EM, Spangler RD, Kerr JS, Cordonnier SA, Hou Y, Dombi E, Kassahun H, Tavernarakis N, Poulton J, Nilsen H, Bohr VA.

J Vis Exp. 2017 Nov 22;(129). doi: 10.3791/56301.

4.

Tomatidine enhances lifespan and healthspan in C. elegans through mitophagy induction via the SKN-1/Nrf2 pathway.

Fang EF, Waltz TB, Kassahun H, Lu Q, Kerr JS, Morevati M, Fivenson EM, Wollman BN, Marosi K, Wilson MA, Iser WB, Eckley DM, Zhang Y, Lehrmann E, Goldberg IG, Scheibye-Knudsen M, Mattson MP, Nilsen H, Bohr VA, Becker KG.

Sci Rep. 2017 Apr 11;7:46208. doi: 10.1038/srep46208.

5.

Mitophagy and Alzheimer's Disease: Cellular and Molecular Mechanisms.

Kerr JS, Adriaanse BA, Greig NH, Mattson MP, Cader MZ, Bohr VA, Fang EF.

Trends Neurosci. 2017 Mar;40(3):151-166. doi: 10.1016/j.tins.2017.01.002. Epub 2017 Feb 9. Review.

6.

NAD+ Replenishment Improves Lifespan and Healthspan in Ataxia Telangiectasia Models via Mitophagy and DNA Repair.

Fang EF, Kassahun H, Croteau DL, Scheibye-Knudsen M, Marosi K, Lu H, Shamanna RA, Kalyanasundaram S, Bollineni RC, Wilson MA, Iser WB, Wollman BN, Morevati M, Li J, Kerr JS, Lu Q, Waltz TB, Tian J, Sinclair DA, Mattson MP, Nilsen H, Bohr VA.

Cell Metab. 2016 Oct 11;24(4):566-581. doi: 10.1016/j.cmet.2016.09.004.

7.

Flavonoid metabolites reduce tumor necrosis factor-α secretion to a greater extent than their precursor compounds in human THP-1 monocytes.

di Gesso JL, Kerr JS, Zhang Q, Raheem S, Yalamanchili SK, O'Hagan D, Kay CD, O'Connell MA.

Mol Nutr Food Res. 2015 Jun;59(6):1143-54. doi: 10.1002/mnfr.201400799. Epub 2015 May 3.

8.

Nuclear receptor-binding protein 1: a novel tumour suppressor and pseudokinase.

Kerr JS, Wilson CH.

Biochem Soc Trans. 2013 Aug;41(4):1055-60. doi: 10.1042/BST20130069. Review.

PMID:
23863178
9.

Differential regulation of chemotaxis: role of Gβγ in chemokine receptor-induced cell migration.

Kerr JS, Jacques RO, Moyano Cardaba C, Tse T, Sexton D, Mueller A.

Cell Signal. 2013 Apr;25(4):729-35. doi: 10.1016/j.cellsig.2012.12.015. Epub 2012 Dec 28.

PMID:
23277202
11.

Nonclinical safety assessment of the histone deacetylase inhibitor vorinostat.

Kerr JS, Galloway S, Lagrutta A, Armstrong M, Miller T, Richon VM, Andrews PA.

Int J Toxicol. 2010 Jan-Feb;29(1):3-19. doi: 10.1177/1091581809352111. Epub 2009 Nov 10.

PMID:
19903873
12.

CCR5 internalisation and signalling have different dependence on membrane lipid raft integrity.

Cardaba CM, Kerr JS, Mueller A.

Cell Signal. 2008 Sep;20(9):1687-94. doi: 10.1016/j.cellsig.2008.05.014. Epub 2008 Jun 3.

PMID:
18573334
13.

Assessment of female and male fertility in Sprague-Dawley rats administered vorinostat, a histone deacetylase inhibitor.

Wise LD, Spence S, Saldutti LP, Kerr JS.

Birth Defects Res B Dev Reprod Toxicol. 2008 Feb;83(1):19-26.

PMID:
18092367
14.

Assessment of developmental toxicity of vorinostat, a histone deacetylase inhibitor, in Sprague-Dawley rats and Dutch Belted rabbits.

Wise LD, Turner KJ, Kerr JS.

Birth Defects Res B Dev Reprod Toxicol. 2007 Feb;80(1):57-68.

PMID:
17294457
15.

Antiangiogenesis and anticancer efficacy of TA138, a novel alphavbeta3 antagonist.

Mousa SA, Mohamed S, Wexler EJ, Kerr JS.

Anticancer Res. 2005 Jan-Feb;25(1A):197-206.

16.

Alpha(v)beta(3) integrin in angiogenesis and restenosis.

Kerr JS, Mousa SA, Slee AM.

Drug News Perspect. 2001 Apr;14(3):143-50.

PMID:
12819820
18.

The alpha v integrin antagonists as novel anticancer agents: an update.

Kerr JS, Slee AM, Mousa SA.

Expert Opin Investig Drugs. 2002 Dec;11(12):1765-74. Review.

PMID:
12457436
19.

The hollow fiber assay.

Hall LA, Krauthauser CM, Wexler RS, Slee AM, Kerr JS.

Methods Mol Med. 2003;74:545-66. No abstract available.

PMID:
12415720
20.

Antisense oligonucleotides selectively regulate aspartyl beta-hydroxylase and its truncated protein isoform in vitro but distribute poorly into A549 tumors in vivo.

Ho SP, Scully MS, Krauthauser CM, Wexler EJ, Stow MD, Dinchuk JE, Kerr JS, Friedman PA.

J Pharmacol Exp Ther. 2002 Aug;302(2):795-803.

PMID:
12130746
21.

An objective procedure for ischemic area evaluation of the stroke intraluminal thread model in the mouse and rat.

Wexler EJ, Peters EE, Gonzales A, Gonzales ML, Slee AM, Kerr JS.

J Neurosci Methods. 2002 Jan 15;113(1):51-8.

PMID:
11741721
22.

Regulation of gene expression and cell growth in vivo by tetracycline using the hollow fiber assay.

Krauthauser CM, Hall LA, Wexler RS, Slee AM, Mitra J, Enders GH, Kerr JS.

Anticancer Res. 2001 Mar-Apr;21(2A):869-72.

PMID:
11396177
23.

Small molecule alpha(v) integrin antagonists: novel anticancer agents.

Kerr JS, Slee AM, Mousa SA.

Expert Opin Investig Drugs. 2000 Jun;9(6):1271-9. Review.

PMID:
11060742
24.

Antiangiogenesis efficacy of nitric oxide donors.

Powell JA, Mohamed SN, Kerr JS, Mousa SA.

J Cell Biochem. 2000 Sep 18;80(1):104-14.

PMID:
11029757
25.

Tumor biology: use of tiled images in conjunction with measurements of cellular proliferation and death in response to drug treatments.

Wexler EJ, Gravallese EM, Czerniak PM, Devenny JJ, Longtine J, Wong MK, Slee AM, Kerr JS.

Clin Cancer Res. 2000 Aug;6(8):3361-70.

26.

The hollow fiber assay: continued characterization with novel approaches.

Hall LA, Krauthauser CM, Wexler RS, Hollingshead MG, Slee AM, Kerr JS.

Anticancer Res. 2000 Mar-Apr;20(2A):903-11.

PMID:
10810375
27.

Novel small molecule alpha v integrin antagonists: comparative anti-cancer efficacy with known angiogenesis inhibitors.

Kerr JS, Wexler RS, Mousa SA, Robinson CS, Wexler EJ, Mohamed S, Voss ME, Devenny JJ, Czerniak PM, Gudzelak A Jr, Slee AM.

Anticancer Res. 1999 Mar-Apr;19(2A):959-68.

PMID:
10368639
28.

The characterization of potent novel warfarin analogs.

Kerr JS, Li HY, Wexler RS, Robinson AJ, Robinson CS, Boswell GA, Krauthauser C, Harlow PP.

Thromb Res. 1997 Oct 15;88(2):127-36.

PMID:
9361366
29.

Involvement of endothelial PECAM-1/CD31 in angiogenesis.

DeLisser HM, Christofidou-Solomidou M, Strieter RM, Burdick MD, Robinson CS, Wexler RS, Kerr JS, Garlanda C, Merwin JR, Madri JA, Albelda SM.

Am J Pathol. 1997 Sep;151(3):671-7.

30.
31.

Behavioural toxicities of antidepressants.

Kerr JS, Fairweather DB, Hindmarch I.

Br J Psychiatry. 1995 Sep;167(3):413-4. No abstract available.

PMID:
7496665
32.

Early murine Lyme carditis has a macrophage predominance and is independent of major histocompatibility complex class II-CD4+ T cell interactions.

Ruderman EM, Kerr JS, Telford SR 3rd, Spielman A, Glimcher LH, Gravallese EM.

J Infect Dis. 1995 Feb;171(2):362-70.

PMID:
7844373
33.
34.

Selective serotonin reuptake inhibitors. Hidden costs ignored.

Hindmarch I, Kerr JS.

BMJ. 1994 Oct 22;309(6961):1083; author reply 1085. No abstract available.

35.

EDU pretreatment decreases polymorphonuclear leukocyte migration into rat lung airways.

Bassett DJ, Elbon CL, Ishii Y, Yang H, Otterbein L, Boswell GA, Kerr JS.

Toxicol Appl Pharmacol. 1994 Jul;127(1):76-82.

PMID:
8048056
36.

EDU decreases polymorphonuclear leukocyte production of reactive oxygen intermediates.

Leanderson P, Zackrisson AL, Tagesson C, Boswell GA, Kerr JS, Bassett DJ.

Res Commun Chem Pathol Pharmacol. 1994 May;84(2):133-41.

PMID:
8090999
38.

2'-substituted chalcone derivatives as inhibitors of interleukin-1 biosynthesis.

Batt DG, Goodman R, Jones DG, Kerr JS, Mantegna LR, McAllister C, Newton RC, Nurnberg S, Welch PK, Covington MB.

J Med Chem. 1993 May 14;36(10):1434-42.

PMID:
8496911
39.

Amnestic effects of triazolam and other hypnotics.

Hindmarch I, Sherwood N, Kerr JS.

Prog Neuropsychopharmacol Biol Psychiatry. 1993 May;17(3):407-13.

PMID:
8475322
40.
41.

IL-1 and its role in rat carrageenan pleurisy.

Goodman R, Mantegna LR, McAilister CL, Bruin E, Dowling RL, George H, Feeser W, Freimark B, Lischwe M, Pick S, Harris RR, Kerr JS.

Mediators Inflamm. 1993;2(1):33-9.

42.

The effects of moclobemide on psychomotor performance and cognitive function.

Fairweather DB, Kerr JS, Hindmarch I.

Int Clin Psychopharmacol. 1993 Spring;8(1):43-7.

PMID:
8473720
43.

Effects of fluoxetine on psychomotor performance, cognitive function and sleep in depressed patients.

Kerr JS, Fairweather DB, Hindmarch I.

Int Clin Psychopharmacol. 1993 Winter;8(4):341-3. No abstract available.

PMID:
8277161
44.

Shape changes due to functional appliances.

Lestrel PE, Kerr JS.

J Calif Dent Assoc. 1992 Dec;20(12):30-6.

PMID:
1283878
45.

The effects of paroxetine, alone and in combination with alcohol on psychomotor performance and cognitive function in the elderly.

Kerr JS, Fairweather DB, Mahendran R, Hindmarch I.

Int Clin Psychopharmacol. 1992 Nov;7(2):101-8.

PMID:
1487621
46.

Synthesis, chemical, and biological properties of vinylogous hydroxamic acids: dual inhibitors of 5-lipoxygenase and IL-1 biosynthesis.

Wright SW, Harris RR, Kerr JS, Green AM, Pinto DJ, Bruin EM, Collins RJ, Dorow RL, Mantegna LR, Sherk SR, et al.

J Med Chem. 1992 Oct 30;35(22):4061-8.

PMID:
1433212
47.

An evaluation of 2-benzyl-1-naphthol (DuP 654) analogs as systemic anti-inflammatory agents.

Kerr JS, Batt DG, Pinto DJ, Stampfli HF.

Res Commun Chem Pathol Pharmacol. 1992 Jul;77(1):77-86.

PMID:
1439183
48.

Measuring the side effects of psychotropics: the behavioural toxicity of antidepressants.

Hindmarch I, Alford C, Barwell F, Kerr JS.

J Psychopharmacol. 1992 Jan;6(2):198-203. doi: 10.1177/026988119200600212.

PMID:
22291351
49.

Correlation between doses of oxazepam and their effects on performance of a standardised test battery.

Kerr JS, Hindmarch I, Sherwood N.

Eur J Clin Pharmacol. 1992;42(5):507-10.

PMID:
1606996
50.

Nutritional aspects of collagen metabolism.

Berg RA, Kerr JS.

Annu Rev Nutr. 1992;12:369-90. Review. No abstract available.

PMID:
1503810

Supplemental Content

Support Center